Koru Medical Systems, Inc. · NASDAQ:KRMD
Koru Medical Systems — Investor Presentation (August 2026)
16 slides from Koru Medical Systems's investor presentation, August 2026
Slide 1: Freedom to Live Life Fully
Freedom to Live Life Fully A Global Leader in Large- Volume Subcutaneous Drug Delivery Nasdaq: KRMD Corporate Overview August 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. All statements that are not historical fact are forward-looking statements. Forward-looking statements dis
Slide 3: Our Company
Our Company We enable, simplify, and enhance the delivery of large-volume subcutaneous (LVSC) drugs in the home and in the clinic More Time For What Matters Most Capitalizing on the ongoing shift from intravenous (IV) hospital settings to subcutaneous (SC) therapy in the home and in infusion clinics
Slide 4: KORU at a Glance
Our Company KORU at a Glance FY2025 REVENUES $41.1M1 75% Domestic Core International Core FREEDOM INTEGRATED INFUSION SYSTEM Pharma Services & Clinical Trials ~60k Global Patients DRUG CLEARANCES / REGISTRATIONS Pharma Services and Domestic & 9 Drugs / 30+ Countries Clinical Trials International Cor
Slide 5: KORU's Freedom Infusion System
Our Company KORU’s Freedom Infusion System Mechanical Pumps ~20% of revenues Customizable Consumables ~80% of revenues Simple, Easy-to-use, 97% Patient Customizable Reusable mechanical adherence rate1 platform for use with pump large-volume SC drugs 1. Rutland B, Bosshard J, Southworth C. Enhancing
Slide 6: Global Ig Business Drives Annual Recurring Revenue Base
Our Ig Franchise Global Ig Business Drives Annual Recurring Revenue Base Global Patient Base Current 510(k) Clearances Patients using the KORU Freedom 7 SCIg drugs from 4 major Infusion System today pharmaceutical manufacturers cleared represent 2.7M+ annual recurring for use on the KORU Freedom Inf
Slide 7: Movement of Healthcare from Hospital to the Home Driving Subcutaneous Infusion Opportunity
Our Opportunity The Movement of Healthcare from Hospital to the Home Driving Large and Growing Subcutaneous Infusion Opportunity Large-Volume Subcutaneous >10ml Infusion SCIg Opportunity Non-Ig Opportunity2 Growing market with <20% SCIg 95+ New Drugs in penetration (vs IVIg) Development >10 mL1 7 la
Slide 8: Shift from IV to SC Driving Large-Volume Subcutaneous Opportunities
Our Opportunity Shift from IV to SC is Driving a Sizeable and Growing Market of Large-Volume Subcutaneous (LVSC) Opportunities On label w/KORU Freedom Infusion System On label w/on-body infusion device Drugs administered with manual push syringe 2 Drugs administered with e-pump system In Clinical De
Slide 9: Oncology Market Opportunity
Enabling New Drugs Oncology Market Opportunity Currently 8 Subcutaneous Oncology Drugs Successful US Pilot Study Validated Value ~$138M Available on the Market Using Syringe Manual Proposition for KORU Push Freedom System in Infusion Clinics 20301 TAM 100% of doses successfully administered ~70%
Slide 10: Pipeline Opportunities in SCIg and New Drug Therapies
Enabling New Drugs Pipeline Opportunities in SCIg and New Drug Therapies 8 in Pipeline 9 on Label Active Opportunities for New Drugs and Indications1 Drugs on KORU’s Freedom Infusion System’s Label Commercial Annual Global SCIg 5.4M3 Annual Infusions Drug Asset Infusions Estimate3 Estimated Deferoxa
Slide 11: Financial Highlights
Financials Financial Highlights Revenue ($M) $47.5M - $48.5M1 1H 2026 1H 2025 Y/Y Δ $50.0 ≈ 19% CAGR +20% (2023-2026) Revenue $23.8M $19.8M Growth $40.0 Strong Gross Margin 63.3% 63.1% +20bps OpEx 13% CAGR Efficiency $30.0 (2016-2023) +9% 22% OpEx $15.3M $14.1M Increase $20.0 60% Net Loss ($0.6M) ($
Slide 12: Strategically Positioned for Accelerated Growth
Outlook Strategically Positioned for Accelerated Long Term Growth Financial Goals3 Recent Accomplishments1 $100M revenue Strong Fundamentals, Significant Opportunity1 18% 2Q26 revenue Large and growing market growth over prior year Accelerated for SC drug delivery; ~95 period double-digit >10mL drug
Slide 13: Sustained Pathway to +20% Growth CAGR
Outlook Sustained Pathway to +20% Growth Key Growth Drivers +20% New drugs CAGR on label Sustained share of SCIg market growth and International share gains expansion 8-10% annual growth (Top-10 market entries) New products New product launches & innovation 2nd generation consumables,Freedom360TM, a
Slide 14: Execution Milestones on Path to Accelerated Revenue Growth
Outlook Execution Milestones on Path to Accelerated Revenue Growth Adjusting 2026 Financial Guidance • 15-18% revenue growth • Positive Adjusted EBITDA, Cash of >$7.5M • Gross margin 62-64% Enable More Drugs, Reach More Patients • Add 4 new pipeline collaborations for FY26: 2 of 4 complete • Deferox
Slide 15: Appendix
(@ KORU Appendix
Slide 16: Non-GAAP Financial Measures
Non-GAAP Financial Measures This presentation includes the non-GAAP financial measures “adjusted EPS”, "adjusted diluted EPS“, and “adjusted EBITDA” that are not in accordance with, nor an alternate to, generally accepted accounting principles and may be different from non-GAAP measures used by othe
KORU Medical Systems — Investor Presentation (August 2026) on 6ix